Merck in Advanced Talks to Buy Seagen in Nearly $40 Billion Deal
Drugmaker Merck & Co is in advanced talks to buy cancer-focused biotech company Seagen Inc in a deal that could be worth roughly $40 billion or more, the Wall Street Journal reported.
Stay updated with breaking news from Biomedical Technology. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Drugmaker Merck & Co is in advanced talks to buy cancer-focused biotech company Seagen Inc in a deal that could be worth roughly $40 billion or more, the Wall Street Journal reported.
The Albany College of Pharmacy is expanding with plans to create regional hub for...
Patients with diabetes or newly recognized hyperglycemia get admitted to every patient service in the hospital and their glycemic management can have a major effect on their outcomes.
Older patients with low-grade, luminal A-type breast cancer may only need endocrine therapy following breast-conserving surgery and could avoid radiation therapy entirely.
The perfusion machine simulated functions of the human body, including blood flow, hormone and nutrient supply, and even the ebb and flow of breathing.